UAE becomes second country to approve gene therapy Itvisma for spinal muscular atrophy
The UAE has become the second country worldwide to approve Itvisma, a gene therapy for spinal muscular atrophy, for adults and children aged two years and older. The therapy replaces the defective gene causing the disease, improving motor function and reducing long-term treatment needs. The approval reflects the UAE’s commitment to rapid access to advanced, life-changing medical innovations.
The UAE has become the second country worldwide to approve Itvisma, a gene therapy for spinal muscular atrophy, for adults and children aged two years and older. The therapy replaces the defective gene causing the disease, improving motor function and reducing long-term treatment needs. The approval reflects the UAE’s commitment to rapid access to advanced, life-changing medical innovations.
